Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METASTATINE: Atorvastatin Pharmaco-metabolomics
NCT03837925Phase 3Completed
- Sponsor
- Société Française de Cardiologie
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular disease (CVD) comparing ATORVASTATIN with PLACEBO (2 arms). Primary endpoint: Trimethylamine N-oxide at 6 weeks. Started Jun 2019; status: completed.
02
Drugs
atorvastatin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT03837925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03837925.